- Home
- About
- Team
- Today's Market
- Premium
- Research it
- Outlook
- Portfolio
- Mobile
- Trust Equitymaster
- Help
- Free Reports
MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- International - indian pharma
- DIVIS LABORATORIES - ACTAVIS (US)
DIVIS LABORATORIES vs ACTAVIS (US) - Comparison Results
DIVIS LABORATORIES 
Change
Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More
ACTAVIS (US)
Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More
Financials
 DIVIS LABORATORIES  ACTAVIS |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| DIVIS LABORATORIES Mar-18 |
ACTAVIS Dec-14 |
DIVIS LABORATORIES/ ACTAVIS |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 1,142 | 19,674 | - | |
| Low | Rs | 533 | 12,001 | - | |
| Sales per share (Unadj.) | Rs | 146.6 | 3,542.8 | - | |
| Earnings per share (Unadj.) | Rs | 33.0 | -442.1 | - | |
| Cash flow per share (Unadj.) | Rs | 38.4 | 325.0 | - | |
| Dividends per share (Unadj.) | Rs | 10.00 | 0 | - | |
| Dividend yield (eoy) | % | 1.2 | 0 | - | |
| Book value per share (Unadj.) | Rs | 222.8 | 7,684.2 | - | |
| Shares outstanding (eoy) | m | 265.47 | 265.90 | - | |
| Bonus/Rights/Conversions | - | - | - | ||
| Price / Sales ratio | x | 5.7 | 4.5 | 127.8% | |
| Avg P/E ratio | x | 25.3 | -35.8 | -70.8% | |
| P/CF ratio (eoy) | x | 21.8 | 48.7 | 44.8% | |
| Price / Book Value ratio | x | 3.8 | 2.1 | 182.3% | |
| Dividend payout | % | 30.3 | 0 | - | |
| Avg Mkt Cap | Rs m | 222,318 | 4,211,205 | 5.3% | |
| No. of employees | `000 | 10.8 | 21.6 | 49.8% | |
| Total wages/salary | Rs m | 4,561 | 0 | - | |
| Avg. sales/employee | Rs Th | 3,616.0 | 43,612.6 | 8.3% | |
| Avg. wages/employee | Rs Th | 423.8 | 0 | - | |
| Avg. net profit/employee | Rs Th | 814.9 | -5,442.4 | -15.0% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 38,915 | 942,031 | 4.1% | |
| Other income | Rs m | 1,134 | -2,351 | -48.2% | |
| Total revenues | Rs m | 40,049 | 939,680 | 4.3% | |
| Gross profit | Rs m | 12,617 | 121,017 | 10.4% | |
| Depreciation | Rs m | 1,425 | 203,984 | 0.7% | |
| Interest | Rs m | 13 | 29,713 | 0.0% | |
| Profit before tax | Rs m | 12,313 | -115,031 | -10.7% | |
| Minority Interest | Rs m | 0 | 0 | - | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | -8,438 | 0.0% | |
| Tax | Rs m | 3,543 | -5,914 | -59.9% | |
| Profit after tax | Rs m | 8,770 | -117,556 | -7.5% | |
| Gross profit margin | % | 32.4 | 12.8 | 252.4% | |
| Effective tax rate | % | 28.8 | 5.1 | 559.7% | |
| Net profit margin | % | 22.5 | -12.5 | -180.6% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 45,351 | 496,330 | 9.1% | |
| Current liabilities | Rs m | 6,507 | 361,970 | 1.8% | |
| Net working cap to sales | % | 99.8 | 14.3 | 699.8% | |
| Current ratio | x | 7.0 | 1.4 | 508.3% | |
| Inventory Days | Days | 127 | 58 | 218.4% | |
| Debtors Days | Days | 95 | 66 | 143.5% | |
| Net fixed assets | Rs m | 21,160 | 115,031 | 18.4% | |
| Share capital | Rs m | 531 | 0 | - | |
| Net worth | Rs m | 59,156 | 2,043,232 | 2.9% | |
| Long term debt | Rs m | 0 | 1,070,694 | 0.0% | |
| Total assets | Rs m | 67,832 | 3,744,571 | 1.8% | |
| Interest coverage | x | 926.8 | -2.9 | -32,277.8% | |
| Debt to equity ratio | x | 0 | 0.5 | 0.0% | |
| Sales to assets ratio | x | 0.6 | 0.3 | 228.0% | |
| Return on assets | % | 12.9 | -2.3 | -552.0% | |
| Return on equity | % | 14.8 | -5.8 | -257.7% | |
| Return on capital | % | 20.8 | -3.0 | -692.1% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 7,759 | 161,765 | 4.8% | |
| From Investments | Rs m | -4,783 | -387,328 | 1.2% | |
| From Financial Activity | Rs m | -3,142 | 217,622 | -1.4% | |
| Net Cashflow | Rs m | -166 | -7,940 | 2.1% | |
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 72.12 Rs / USD
Compare DIVIS LABORATORIES With: MYLAN (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Compare DIVIS LABORATORIES With: SUVEN LIFE PANACEA BIOTECH J.B.CHEMICALS DR. REDDYS LAB WOCKHARDT LTD.
|
| |
Today's Market
Sensex Ends 118 Points Higher; Realty and Banking Stocks Witness Buying(Closing)
Indian share markets continued to trade on a positive note during closing hours of trade and ended the day marginally higher.
Related Views On News
DIVIS LABORATORIES Announces Quarterly Results (2QFY19); Net Profit Up 92.3% (Quarterly Result Update)
Nov 9, 2018 | Updated on Nov 9, 2018For the quarter ended September 2018, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 92.3% YoY). Sales on the other hand came in at Rs 13 bn (up 44.3% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.
DIVIS LABORATORIES Announces Quarterly Results (1QFY19); Net Profit Up 50.8% (Quarterly Result Update)
Aug 6, 2018 | Updated on Aug 6, 2018For the quarter ended June 2018, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 50.8% YoY). Sales on the other hand came in at Rs 10 bn (up 21.2% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
Shalby Ltd. (IPO)
Dec 2, 2017Should you subscribe to the IPO of Shalby Ltd?
The Power of 5 Minutes (The 5 Minute Wrapup)
Jun 16, 2017Here's what you can expect from The 5 Minute Wrapup in the coming months and years.
More Views on NewsMost Popular
These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)
Nov 9, 2018All blue chip companies are large caps but all large caps are not blue chips.
Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)
Nov 6, 2018If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.
Insider Buying: These Owner Operators Are Taking Advantage of the Correction(Chart Of The Day)
Nov 2, 2018We believe insider buying is one of the strongest smart money indicators.
Are Fund Houses Opening Up Their NFO Factories Again?(Outside View)
Nov 2, 2018PersonalFN sheds light on FY 2018-19 so far, the mutual fund industry has collectively launched 84 New Fund Offers (NFOs), of which some are still open for subscription.
Does it Make Sense to Invest in Offshore Funds?(Outside View)
Nov 6, 2018Many investors prefer to invest in offshore funds because of the rupee depreciation and on-going downtrend in the markets, but it is to be invested only when there is no option available to invest in India.
More|
| |
DIVIS LABORATORIES SHARE PRICE
Nov 15, 2018 03:35 PM
TRACK DIVIS LABORATORIES
- Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON DIVIS LABORATORIES
DIVIS LABORATORIES 5-YR ANALYSIS
COMPARE DIVIS LABORATORIES WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.